7 news items
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
ELTX
10 Jun 24
of Medical Oncology & Hematology and the R.J. Zuckerberg Cancer Center, and scientific investigator at Northwell Health.Elicio Therapeutics
Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
23 May 24
announced preliminary data from the ongoing AMPLIFY-7P Phase 1a study of its off-the-shelf investigational therapeutic cancer vaccine candidate, ELI
Elicio Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Updates
ELTX
15 May 24
investigational
Elicio Therapeutics to Present New Preliminary Data from the Ongoing AMPLIFY-7P Phase 1/2 Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting
ELTX
25 Apr 24
-peptide formulation of Elicio's off-the-shelf investigational therapeutic cancer vaccine candidate, ELI-002 7P, in patients with mKRAS-driven solid tumors
Elicio Therapeutics (NASDAQ: ELTX) Makes Strides In Growing Cancer Vaccination Industry
ELTX
11 Apr 24
in its pipeline: ELI-002, ELI-007 and ELI-008. ELI-002 is Elicio's lead investigational asset
aocuu8zx2u96i138h3hw1a98ouib8i7dlo
ELTX
5 Apr 24
announced that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research ("AACR
e8b7ikt59tr0vr343oozaxw5oylo31gynbmuhwiyvjrmd9ywk53
ELTX
5 Apr 24
that it will be sharing pipeline updates for all investigational candidates at the upcoming American Association for Cancer Research ("AACR") Annual Meeting
- Prev
- 1
- Next